Name : Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein
Product Source :
Recombinant Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein is expressed from E.coli with with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide.[Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK]
Molecular Weight :
The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR at 5μg/ml (100μl/well) on the plate. Dose response curve for Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag with the EC50 of 66.0ng/ml determined by ELISA (QC Test). SPR Data Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag captured on CM5 Chip via anti-his antibody can bind HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR with an affinity constant of 6.93 nM as determined in SPR assay (Biacore T200).
Background :
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Synonyms :
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
References & Citations :
(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
MBL2/COLEC1 Protein
IFN-alpha 5/IFNA5 Protein
Popular categories:
Carbonic Anhydrase 5B (CA-VB)
PLGF